Chimerix (CMRX) was a prime acquisition candidate for Jazz Pharmaceuticals (JAZZ) due to dordaviprone's unique positioning and likely near-term approval to treat H3-K27M mutant glioma, Wedbush said in a note Wednesday.
Jazz said Wednesday it agreed to acquire Chimerix for $8.55 per share in an all-cash deal, about a 72% premium over its previous closing price and in-line with the estimated fair value of dordaviprone, the investment firm said.
There does not appear to be any antitrust issues because Jazz does not have a presence glioma, Wedbush said.
Wedbush downgraded Chimerix to neutral from outperform and raised its price target to $8.55, reflecting the cash tender offer.
Shares of Chimerix were up almost 69% in recent trading.
Price: 8.43, Change: +3.47, Percent Change: +69.96
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。